Replies to post #563969 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

A comprehensive overview of the independent peer review is available at the link below. Explore all of the supplements attached to the JAMA publication and the podcast interview with Dr. Liau included on the JAMA Oncology website page for the murcidencel (DCVax-L) study.

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

This video is about the P3 that was published in JAMA Oncology, but Dr. Toms also briefly mentions of the pembrolizumab combo study at UCLA at about timestamp 6:30. The PD1 combo study has reached its midpoint and the interim survival data are astonishing.

https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/





https://ceoworld.biz/2022/04/05/top-5-medical-journals-in-the-world-everyone-should-know-about/

[SkyLimit2022]

Thanks for referring to the forthcoming regulatory process.

RAs around the world are involved and will have the opportunity to approve the murcidencel cell-based technology for patients in their respective nations or union of nations. Northwest Biotherapeutics is preparing RA filings and manufacturing capacity to address a global market.

Watch for the forthcoming NICE developments. They will further validate the P3 data and the significance of this landmark study. These developments have recently begun to update in recent postings on the NICE website and significant developments could further unfold in advance of the FDA.

https://www.nice.org.uk/guidance/indevelopment/gid-ta10143

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847